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Background: The longevity of an organism is influenced by both genetic and environmental factors. With respect
to genetic factors, a significant effort is being made to identify pharmacological agents that extend life span by
targeting pathways with a defined role in the aging process. On the environmental side, the molecular mechanisms
responsible for the positive influence of interventions such as dietary restriction are being explored. The
environment experienced by humans in modern societies already contains countless compounds that may
influence longevity. Understanding the role played by common compounds that substantially affect the aging
process will be critical for predicting and interpreting the outcome of introducing new interventions. Caffeine is the
most widely used psychoactive drug worldwide. Prior studies in flies, worms, and mice indicate that caffeine may
positively impact age-associated neurodegenerative pathology, such as that observed in Alzheimer’s disease.
Results: Here we report that caffeine is capable of extending life span and improving healthspan in Caenorhabditis
elegans, a finding that is in agreement with a recently published screen looking for FDA-approved compounds
capable of extending worm life span. Life span extension using caffeine displays epistatic interaction with two
known longevity interventions: dietary restriction and reduced insulin signaling. Caffeine treatment also delays
pathology in a nematode model of polyglutamine disease.
Conclusions: The identification of caffeine as a relevant factor in aging and healthspan in worms, combined with
prior work in both humans and rodents linking caffeine consumption to reduced risk of age-associated disease,
suggests that caffeine may target conserved longevity pathways. Further, it may be important to consider caffeine
consumption when developing clinical interventions, particularly those designed to mimic dietary restriction or
modulate insulin/IGF-1-like signaling. The positive impact of caffeine on a worm model of polyglutamine disease
suggests that chronic caffeine consumption may generally enhance resistance to proteotoxic stress and may be
relevant to assessing risk and developing treatments for human diseases like Alzheimer’s and Huntington’s disease.
Future work addressing the relevant targets of caffeine in models of aging and healthspan will help to clarify the
underlying mechanisms and potentially identify new molecular targets for disease intervention.
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Numerous interventions have been identified that extend
life span across an evolutionarily diverse range of organ-
isms [1,2]. These include external (environmental) inter-
ventions, such as dietary restriction, heat shock, or
treatment with a pharmacological agent, as well as in-
ternal (genetic) interventions, such as reduced target of
rapamycin (TOR) signaling or reduced insulin/IGF-1-
like signaling (IIS). In most cases, studies identifying
these interventions are carried out using a genetically
homogenous population in a controlled, low-risk, and
pathogen-free environment. Interventions that are suc-
cessful under laboratory conditions are beginning to be
introduced into human clinical trials. As these trials pro-
gress, it will be important to understand how the artifi-
cial nature of the populations and environments in the
laboratory setting may impact the outcomes of specific
interventions when applied under more variable condi-
tions. In terms of genetics, efforts are underway to
understand the effects of dietary restriction in genetically
heterogeneous populations. Early evidence indicates that
the benefits observed in laboratory populations might
not be universally realized by all members of genetically
diverse populations [3-7]. From an environmental per-
spective, human populations are exposed to a wide range
of diets, climates, and pharmacological agents that are
not present in the laboratory setting. Understanding the
impact of these factors on longevity and age-associated
disease will be important for predicting unintended
effects that might arise from introducing novel
interventions.
Caffeine is the most widely used psychoactive sub-
stance worldwide. Average consumption in the US is
168 mg/person/day (equivalent to 1 to 2 cups of Star-
bucksW coffee) and reaches 414 mg/person/day in the
Netherlands [8]. Chronic, moderate consumption of caf-
feine has been linked with reduced risk of age-associated
neurodegenerative disorders in humans, including de-
mentia [9], Alzheimer’s disease [9-11], and Parkinson’s
disease [12-15]. In addition, studies performed on elderly
human populations have correlated habitual caffeine
consumption with reduced mortality [16,17] and
improvements in various measures of healthspan, in-
cluding reduced cognitive decline [18,19], improved
memory [20-22], and increased motor speed [20]. While
other studies failed to find similar correlations, the dif-
ferences are attributed to wide variation in methodology
[23,24].
The potential for caffeine consumption to reduce
neuropathology and impart age-associated neuroprotec-
tion has motivated numerous studies using animal mod-
els. Research using rodent models of neurodegenerative
disease generally demonstrates that caffeine administra-
tion can successfully alleviate degenerative symptomsand pathology (review by Cunha and Agostinho [25]).
Acute treatment with caffeine prevents avoidance mem-
ory impairment in a rat model of Parkinson's disease
[26], while chronic caffeine treatment prevents cognitive
defects in mice expressing toxic forms of amyloid beta, a
common rodent model of Alzheimer’s disease [27]. Fur-
thermore, acute caffeine treatment reduces amyloid beta
levels in the plasma and brain interstitial fluid [28] and
delays memory defects following intracerebral adminis-
tration of amyloid beta [29-31]. One study using these
mice suggests that caffeine treatment may even restore
performance in individuals that are already displaying
memory deficits [32]. Neurodegenerative disorders aside,
caffeine treatment also prevents memory impairment in
rodent models of various other diseases and conditions,
including chronic stress, child convulsions, type 1 and
type 2 diabetes, attention deficit and hyperactivity dis-
order, heavy alcohol consumption, and sleep deprivation
[25]. Importantly, caffeine improves age-associated
memory impairment in both mice and rats [33,34].
Recently, several groups have started investigating the
physiological effects of caffeine in non-mammalian mod-
els, including worms and yeast. A common strategy to
model Alzheimer’s disease in Caenorhabditis elegans
involves transgenic expression of a toxic form of amyloid
beta in the body wall muscle, resulting in an age-
dependent paralysis phenotype [35]. Dostal et al. [36]
found that both caffeine and non-caffeine components
of coffee were capable of delaying paralysis in this
model. During the course of the present study, another
group identified caffeine in a screen for FDA-approved
compounds capable of extending worm life span [37]. In
yeast, caffeine increases chronological life span, likely
through a mechanism related to TOR signaling [38].
Given the high consumption rates of caffeine for
people living in the developed world, understanding the
impact of caffeine on aging and age-related disease will
be important as aging interventions move from the la-
boratory into use in clinical trials and the broader popu-
lation. In this study, we characterize the effect of
caffeine on life span and healthspan in C. elegans and
identify clear epistatic interactions between caffeine and
both dietary restriction and reduced IIS.
Results
Caffeine extends worm life span in a temperature-
dependent manner
In order to determine whether caffeine impacts longev-
ity, life span was measured for worms maintained
throughout their adult life on nematode growth medium
(NGM) plates containing caffeine. In previous work, we
observed temperature-dependent effects on life span
resulting from reduced expression of the hypoxia-
inducible factor, hif-1 [39]. Specifically, hif-1 knockdown
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examine the possibility that caffeine might display a
similar dependence on temperature, we measured life
span for worms at 15°C, 20°C, and 25°C in the presence
of 0 mM, 5 mM, or 7.5 mM caffeine. Caffeine concen-
trations were selected based on previous studies in yeast
and worms [36,38,40,41]. In contrast to hif-1 knock-
down, caffeine extended life span at 15°C and 20°C, and
slightly shortened life span at 25°C (Figure 1; Additional
file 1: Table S1). These data are in agreement with the
recently published FDA-approved drug screen that
reported 29.4% median life span extension resulting
from 0.1% (5.15 mM) caffeine at 20°C [37].
Next, we conducted a caffeine dose response with re-
spect to life span in order to determine the optimal
temperature and caffeine concentration for increasing
longevity. Life span extension was observed for caffeine
concentrations ranging from 0.5 mM to 10 mM at
20°C and from 5 mM to 20 mM at 15°C (Figure 2;
Additional file 1: Table S1). The highest mean life span
extension (36.7%) was achieved at 15°C using 10 mM caf-
feine (Figures 2A,C; Additional file 1: Table S1). The high-
est mean life span extension (16.9%) at 20°C also occurred
at 10 mM (Figure 2B,C; Additional file 1: Table S1). Caf-
feine reduced life span at concentrations of 30 mM or
greater at both temperatures (Figure 2; Additional file 1:
Table S1).
Caffeine prolongs mobility and delays polyglutamine-
associated pathology
An intervention that increases longevity does not neces-
sarily extend healthspan, the time period over which an
organism remains healthy. To assess the effect of caf-
feine on C. elegans healthspan, we examined two types
of movement throughout the life span of worms exposed
to either 0 mM or 5 mM caffeine. Caffeine delayed age-
associated decline in both the thrashing rate in liquid
and the rate of travel on solid media in the presence of a
bacterial food source (Figure 3).
Two previous studies found that caffeine can prolong
survival [37] and delay the onset of paralysis [36] in a
worm model of Alzheimer’s disease in which amyloid
beta is express in the body wall muscles [42]. DostalFigure 1 Caffeine treatment results in a temperature-dependent life s
5 mM or 7.5 mM caffeine throughout adult life increases life span at 15°C aet al. [36] used an inducible amyloid beta construct that
resulted in a severe proteotoxic pathology causing un-
treated worms to become paralyzed over the course of
20 to 30 h at 20°C. In order to examine the effect of caf-
feine in a similar model of age-associated proteotoxicity,
we examined paralysis in worms expressing an aggre-
gate-prone, YFP-tagged polyglutamine chain (Q35::YFP)
in the body wall muscles. Expanded polyglutamine tracts
are a known causative factor in Huntington’s disease and
related neurodegenerative disorders in humans, though
the underlying disease mechanism is not known [43].
Q35::YFP worms display a similar—but more slowly pro-
gressing—paralysis phenotype to the amyloid beta
worms, with the majority of worms becoming paralyzed
over the course of approximately 3 weeks. Similar to the
results of the amyloid beta study, we found that caffeine
delayed the onset of paralysis in Q35::YFP worms at
both 15°C and 20°C (Figure 4A,B). Caffeine also delayed
the onset of paralysis at 25°C (Figure 4C), despite the
lack of life span extension (Figure 1), suggesting that caf-
feine may influence life span and proteotoxicity through
at least partially distinct mechanisms. We further exam-
ined Q35::YFP aggregate formation as a secondary mar-
ker of polyglutamine toxicity. Similar to the case for
paralysis, caffeine reduced the number of aggregates
formed during early adulthood (Figure 4D).
Life span extension by bacterial deprivation and exposure
to caffeine are non-additive
Dietary restriction is the most widely studied interven-
tion capable of increasing life span. One goal of dietary
restriction research is to discover dietary restriction
mimetics, pharmacological agents capable of reprodu-
cing the beneficial effects of dietary restriction without a
reduction in food intake [44,45]. In order to investigate
the potential for caffeine to act as a dietary restriction
mimetic, we measured life span for worms with com-
bined exposure to both caffeine and bacterial
deprivation, a form of dietary restriction in which the
bacterial food source is completely removed after the
worms have reached early adulthood [46-48]. Both caf-
feine and bacterial deprivation extended life span when
applied to worms independently, but did not produce anpan extension in worms. Maintenance of worms in the presence of
nd 20°C, but not at 25°C.
Figure 2 Caffeine extends worm life span at 15°C and 20°C. (A) Caffeine concentrations in the 5 to 20 mM range increase life span at 15°C.
(B) Caffeine concentrations in the 0.5 to 10 mM range increase life span at 20°C. (C) Caffeine dose response curves reveal optimal concentrations
for increased life span. *P < 0.05 vs. 0 mM at the same temperature.
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20°C (Figure 5A,B; Additional file 1: Table S1). In fact,
bacterial deprivation became detrimental to life span
when worms were subjected to caffeine concentrations
of 30 mM or greater (Figure 5A,B; Additional file 1:
Table S1). The abrogation of life span extension result-
ing from bacterial deprivation in the presence of caf-
feine is consistent with the idea that caffeine and dietary
restriction influence aging via similar downstream
mechanisms. Importantly, caffeine does not mimic diet-
ary restriction by limiting food intake via reduced
pharyngeal pumping (Figure 5C), as is the case with
long-lived eat-2 mutants [49,50].
Caffeine extends life span in the absence of sir-2.1,
hif-1, and cep-1
Several genetic pathways are known to influence longevity
and may mediate the life span-extending effects ofFigure 3 Caffeine delays age-associated decline in mobility at 15°C. W
(A) and travel rate (B) compared to untreated control worms. Error bars repcaffeine. In order to identify interactions between caffeine
and canonical aging pathways, we measured the effect of
caffeine on life span for strains with loss of function muta-
tions in (1) sir-2.1, which encodes the worm ortholog of
Sir2, a histone deacetylase linked to aging in many species;
(2) hif-1, which encodes the hypoxia-inducible factor; or
(3) cep-1, the worm ortholog of the tumor suppressor p53.
Based on prior studies showing that bacterial deprivation
can increase the life span of worms mutated for either
sir-2.1 or hif-1 [46,48,51], we predicted that caffeine would
also increase life span in these backgrounds. Consistent
with this prediction, caffeine increased the life span of
sir-2.1(ok434) and hif-1(ia4) animals (Figure 6A,B,D;
Additional file 1: Table S1). Caffeine also increased the life
span of cep-1(gk138) animals (Figure 6A,C; Additional
file 1: Table S1), indicating that the action of caffeine on
life span is at least partially independent of all three of
these genes, although the magnitude of effect of caffeineorms in the presence of 5 mM caffeine displayed increased thrashing
resent standard error. *P < 0.05 vs. 0 mM on the same day.
Figure 4 Caffeine delays age-associated paralysis in a worm polyglutamine toxicity model. Caffeine treatment delayed the onset of
paralysis in worms expressing Q35::YFP in their body wall muscles at (A) 15°C, (B) 20°C, and (C) 25°C. (D) Caffeine reduced the formation
of Q35::YFP aggregates at 15°C. Error bars represent standard error. *P < 0.05 vs. 0 mM.
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smaller than that observed in wild-type animals at the
same concentrations.
Caffeine appears to modulate longevity by a mechanism
similar to reduced IIS signaling
The IIS pathway is the most widely studied longevity path-
way in C. elegans. Interventions or mutations that reduceFigure 5 Caffeine increases life span in a manner that is non-additive
bacterial deprivation are non-additive at (A) 15°C and (B) 20°C; *P < 0.05 vs
caffeine does not reduce pharyngeal pumping at 15°C. Error bars representIIS, such as RNAi knockdown of the insulin-like receptor
DAF-2, increase life span by activating the FOXO family
transcription factor DAF-16 [2]. Treatment with 5 mM
caffeine failed to extended life span of daf-16(mu86) mu-
tant worms (Figure 7A,B; Additional file 1: Table S1). This
result is in agreement with a similar finding by Lublin
et al. [37] at 20°C and suggests a functional link between
caffeine and IIS. To further explore the link betweenwith dietary restriction. Life span extension from caffeine and
. ad libitum fed worms at the same caffeine concentration. (C) 5 mM
standard error. *P < 0.05 vs. 0 mM on the same day.
Figure 6 Caffeine extends life span of canonical longevity mutants. Treatment with 5 mM or 10 mM caffeine extends life span of
(A) wild-type, (B) sir-2.1(ok434), (C) hif-1(ia4), and (D) cep-1(gk138) worms.
Figure 7 Caffeine displays epistatic interaction with IIS components. 5 mM or 10 mM caffeine extends life span in wild-type (A), but not
daf-16(mu86) (B), worms, and in wild-type worms fed EV(RNAi) (C), but not worms fed daf-16(RNAi) (D) or daf-2(RNAi) (E).
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able of extending life span in worms when daf-16 or daf-2
was knocked down using RNAi. As with mutation of
daf-16, 5 mM caffeine failed to increase life span in worms
subjected to daf-16(RNAi) (Figure 7C,D; Additional file 1:
Table S1). In both the case of the daf-16(mu86) mutant and
the case of wild-type worms subjected to daf-16(RNAi),
10 mM caffeine increased life span, though to a much smal-
ler degree than in a wild-type background or in worms sub-
jected to EV(RNAi). This may suggest that a small
mechanistic component of the life span extension observed
in the presence of caffeine is independent from IIS. Neither
5 mM nor 10 mM caffeine further increased the long life
span of worms subjected to daf-2(RNAi) (Figure 7C,E;
Additional file 1: Table S1).
Activity of DAF-16 is post-translationally regulated
through subcellular localization. Reduction of IIS causes
dephosphorylation of the DAF-16 protein, allowing it to
enter the nucleus and thereby activate transcription of
target genes. In order to determine whether caffeine
influences DAF-16 localization in a this manner, we
examined transgenic worms expressing a GFP-tagged
DAF-16 protein (DAF-16::GFP). Worms exposed to caf-
feine for 2–3 h displayed an increase in DAF-16::GFP
nuclear localization compared to untreated controls
(Figure 8). These data are consistent with a model in
which caffeine impacts life span, at least in part, by redu-
cing insulin signaling and activating DAF-16.
We next asked whether DAF-16 is necessary for caffeine
to delay paralysis in the Q35::YFP polyglutamine toxicity
model. Intriguingly, caffeine was capable of delaying par-
alysis of the Q35::YFP worms even in the presence of
daf-16(RNAi) (Figure 9), adding further support for a
model in which caffeine impacts life span and polygluta-
mine toxicity through at least partially distinct mechanisms.
Discussion
In this study, we demonstrate that chronic exposure to
caffeine during adulthood extends life span andFigure 8 Caffeine causes DAF-16 nuclear localization. (A) Treatment w
expressed DAF-16::GFP. A 2-h heat shock at 37°C robustly activates DAF-16
*P < 0.05 vs. 0 mM. (B) Representative image showing DAF-16::GFP nuclearhealthspan of C. elegans in a temperature-dependent
manner. Life span extension from caffeine is non-
additive with life span extension by bacterial deprivation
and independent of the hypoxia inducible factor, HIF-1,
the C. elegans p53 ortholog, CEP-1, and the C. elegans
Sir2 ortholog, SIR-2.1. Caffeine appears to act, at least in
part, by activating the FOXO transcription factor DAF-16
in a manner similar to reduced IIS. Chronic caffeine ex-
posure also delays paralysis in a C. elegans model of poly-
glutamine disease, though this effect appears to be
independent of DAF-16.
Perhaps the most intriguing therapeutic value for caf-
feine is its potential to reduce the risk and delay the
onset of age-associated neurodegenerative disease. As
described in the introduction, studies in humans and
rodents indicate that caffeine treatment reduces the risk
of disease onset and improves cognitive decline in mod-
els of Alzheimer’s and Parkinson’s disease. Previous work
has also shown that caffeine is capable of delaying path-
ology in worm models of Alzheimer’s disease [36,37]. In
this study, we expand upon these findings to show that
caffeine is capable of delaying pathology in a worm
model of polyglutamine disease. Although mammalian
studies investigating the use of caffeine in neurodegen-
erative disorders have focused primarily on Alzheimer’s
and Parkinson’s disease, research that examines the
effects of caffeine consumption on Huntington’s disease
in human populations is currently underway. Our find-
ing suggests that a more detailed examination of the in-
fluence of caffeine on the progression of a broader
spectrum of diseases associated with proteotoxic stress
in mammalian models may be warranted.
This study and that by Lublin et al. [37] both identify
an epistatic interaction between caffeine and IIS. A
related link has been made in mammals. While acute
treatment with caffeine has been shown to increase
blood pressure [52] and reduce insulin sensitivity
[53,54], long-term coffee consumption shows a strong
correlation with reduced risk of type 2 diabetes inith 5 mM caffeine causes nuclear localization of transgenically
and was used as a positive control. Error bars represent standard error.
localization in response to caffeine.
Figure 9 Caffeine delays age-associated paralysis associated with polyglutamine toxicity independently from DAF-16. Caffeine
treatment delayed the onset of paralysis in worms expressing Q35::YFP in their body wall subject to either EV(RNAi) or daf-16(RNAi) at 15°C.
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diet-induced insulin resistance and hypertension in rats
[56]. Chronic caffeine consumption may prove useful in
mimicking reduced IIS and improving diet-induced insu-
lin resistance.
The interaction observed between bacterial deprivation
and caffeine suggests that caffeine may also emulate
aspects of dietary restriction, which is particularly inter-
esting given that caffeine is already in common use in
human society. The observation that caffeine interacts
with both bacterial deprivation and IIS is complicated by
the fact that bacterial deprivation extends life span inde-
pendently of both DAF-2 and DAF-16 [46,48], suggest-
ing that caffeine may activate overlapping downstream
targets in both pathways. The additional observation
that life span extension from caffeine is reduced in three
other strain backgrounds with mutations in genes linked
to aging suggests that caffeine may be activating a com-
mon set of cellular processes important for increased
longevity via a range of interventions. The idea that caf-
feine may interact with multiple pathways involved in
aging is further supported by the observation that the
influences of caffeine on life span and polyglutamine
toxicity are separable with respect to their dependence
on both temperature and DAF-16. Alternatively, it is
possible that caffeine alters the molecular or physio-
logical state of the organisms in such a way that renders
the organism unable to respond normally to signals that
result in increased life span in untreated animals. Epi-
static interactions provide limited information regarding
the potential mechanism of life span extension [57], and
further study will be required to unravel the complex-
ities of caffeine’s impact on the aging process.
This study identifies genetic interaction between caf-
feine and both the IIS and the dietary restriction path-
ways. The direct molecular targets and downstream
mechanisms by which caffeine influences longevity re-
main to be investigated. Mammalian research suggests
that caffeine primarily impacts cognitive phenotypes by
antagonizing adenosine receptors A1 and A2A [25]. At
sub-toxic levels of caffeine, adenosine receptors are theonly clear molecular targets and many of the beneficial
effects of caffeine are mimicked by specific agonists of
adenosine receptor A2A [25]. Mild inhibition of
phosphodiesterase activity has only been observed at
higher concentrations of caffeine [58]. Functionally, caf-
feine prevents memory impairment induced by heavy al-
cohol consumption in rats, an effect that can be
mimicked by simultaneous treatment with inhibitors of
phosphodiesterase 5 and adenosine receptor A2A (but
not by either inhibitor alone) [58]. This suggests that
specific subclasses of phosphodiesterases may be import-
ant for the action of sub-toxic doses of caffeine in some
circumstances.
Clear orthologs of mammalian adenosine receptors
have not yet been identified in C. elegans, though there
are several candidate genes based on sequence hom-
ology. In contrast, the C. elegans genome contains six
phosphodiesterases that fall into two functional classes:
one class that specifically targets cAMP (PDE-4,6) and
another that is thought to target cGMP (PDE-1,2,3,5)
[59,60]. High doses of caffeine have been shown to in-
hibit mammalian cAMP phosphodiesterases [61,62], in-
dicating that the former class is of greater interest.
Further investigation will determine whether adenosine
receptors, phosphodiesterases, or other targets are
involved in caffeine’s effect on worm life span.
Two factors have complicated mammalian research
with caffeine. In human populations, most studies deter-
mine caffeine intake by consumption of caffeine-
containing foods and beverages, such as coffee, tea, soft
drinks, and chocolate, all of which contain other com-
pounds that have the potential to affect the diseases
under investigation. For example, one study found that
long-term coffee consumption shows a strong correl-
ation with reduced risk of type 2 diabetes [55], while a
later study found a similar correlation for both caffein-
ated and decaffeinated coffee consumption [63]. A re-
cently published study identified a correlation between
consumption of either caffeinated or decaffeinated coffee
and reduced mortality risk for a range of age-associated
diseases, including diabetes [64]. The collective findings
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related benefit from coffee consumption may result from
compounds in coffee other than caffeine. Interpretations
are further complicated by seemingly contradictory effects
resulting from acute and chronic caffeine treatment in
some circumstances, as discussed previously with respect
to insulin sensitivity and hypertension. C. elegans may be
a useful model for decoupling these types of complica-
tions. For example, worm studies completed to date have
already begun to separate influences from caffeine and
non-caffeine sources with respect to coffee. Dostal et al.
[36] identified SKN-1 as a primary downstream factor in
the caffeine-independent delay in amyloid beta toxicity
using coffee extract, while this study and that by Lublin
et al. [37] identify IIS as an important player in life span
extension by caffeine.
A growing accumulation of evidence in humans,
rodents, and nematodes suggests that chronic caffeine
exposure may yield significant health benefits by delay-
ing aging and preventing specific age-associated patholo-
gies. Recent studies indicate that C. elegans will be a
useful system for dismantling the molecular events that
underlie the beneficial effects of caffeine. C. elegans re-
search may also help unravel the complications asso-
ciated with acute versus chronic caffeine treatment and
identify other compounds in coffee and tea with the po-
tential to promote longer life span. Overall, based on the
observations that caffeine is capable of increasing life
span in worms and has been correlated with decreased
mortality in humans, we anticipate the expansion of
studies examining the influence of caffeine on longevity
into mammalian systems.
Conclusion
In this study, we have validated and extended prior evi-
dence that caffeine can improve healthy aging in C. elegans
by showing that caffeine can both increase life span and
promote resistance to proteotoxic stress. The longevity
effects of caffeine appear to overlap with both the insulin-
like signaling pathway and with dietary restriction, while
the resistance to polyglutamine toxicity is independent of
insulin-like signaling. The effects of caffeine on longevity
also vary based on the experimental temperature. It will be
important to unravel the mechanisms underlying these
observations in future studies. In this way, it may be pos-
sible to define how caffeine exerts its positive health bene-
fits in worms and determine whether similar processes




The strains used in this study are listed in Additional file 1:
Table S2 and were obtained from the CaenorhabditisGenetics Center, the laboratory of Dr. Chris Link (Univer-
sity of Colorado, Boulder, CO, USA), or the laboratory of
Dr. Jim Thomas (University of Washington, Seattle, WA,
USA). Animals were maintained on solid nematode growth
media (NGM) agar plates using standard techniques.
Experiments were performed on NGM plates supplemen-
ted with 25 mg/ml ampicillin to prevent contamination.
Adult worms were placed on NGM plates containing FUdR
to prevent reproduction. With the exception of the bacteria
used in RNAi experiments, bacterial food was killed by ex-
posure to UV and addition of ampicillin to the medium, as
previously described [65]. Solid anhydrous caffeine (MP
Biomedicals, Solon, OH, USA) was added directly to the
NGM solution prior to autoclaving. Neither autoclaving
nor UV treatment during plate preparation influenced life
span in the presence of caffeine (data not shown). All
experiments were conducted at 15°C except where other-
wise noted.RNAi
RNAi experiments were conducted using feeding proto-
cols according to standard procedures. The RNAi feed-
ing strains targeting daf-16 and daf-2 were obtained
from the Vidal RNAi library [66] and J. McElwee, re-
spectively. RNAi plasmids were sequenced to verify the
target sequence. RNAi plates consisted of NGM supple-
mented with 1 mM β-D-isothiogalactopyranoside
(IPTG) and 25 μg/ml carbenicillin. Worms were raised
on RNAi bacteria from egg to the L4 stage of develop-
ment and then transferred to plates containing freshly
seeded RNAi bacteria plus 50 μM FUdR to prevent
production.Life span analysis
Life span experiments were conducted as previously
described [65]. Bacterial deprivation was conducted by
maintaining animals on UV-killed OP50 bacteria food
until day 4 of adulthood and then transferring animals
to NGM agar plates containing ampicillin but without a
bacterial food source, as previously described [47,67].Paralysis analysis
Paralysis of worms was assessed visually as previously
described [68]. Worms were scored as paralyzed if they
were unable to make forward progress on the NGM sur-
face in response to plate-tapping or tail-prodding.Quantification of aggregates
Q35::YFP aggregates were quantified by taking images
using fluorescent microscopy followed by automated
quantification of the number of aggregates present per
worm based on pixel density using ImageJ.
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Thrashing was quantified visually by suspending individ-
ual animals in a droplet of M9 buffer on the surface of
an NGM plate and counting the number of body bends
in 60 s. Movement rate was quantified by placing an in-
dividual worm onto a fresh OP50-seeded NGM plate.
After 60 min, pictures were taken of tracks left in the
bacterial lawn using a standard SLR camera with a
microscope eyepiece adapter. Track length was mea-
sured using ImageJ software. Pharyngeal pumping was
quantified visually by taking video recordings of the head
region of individual animals and counting the number of
pumps in 30 s.
DAF-16::GFP nuclear localization
Transgenic worms expressing DAF-16::GFP were trans-
ferred to plates containing 0 mM or 5 mM caffeine at
the L4 stage of development for. A third population of
worms was exposed to 30°C for 2 h immediately prior to
analysis. Worms were immobilized by treatment with 25
nM NaN3 and still images captured using a mounted
digital camera and the GFP fluorescence channel of a
Zeiss SteREO Lumar V.12 microscope. Captured images
were used to quantify visible GFP foci.
Statistical analysis
Statistical significance was determined for worm life
span using the Wilcoxon rank sum test. All other com-
parisons were conducted using an unpaired two-tailed
Student’s T-test assuming unequal variance.
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Additional file 1: Table S1. Summary of life span data in this study.
Table S2. Strains used in this study.
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